These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 25844889)

  • 1. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
    Choi MK; Song IS
    J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
    Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
    Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
    Miller DW; Hinton M; Chen F
    Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation and efflux of ATP-binding cassette transporter substrate 2,4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments.
    Vaidya SS; Walsh SW; Gerk PM
    Mol Pharm; 2009; 6(6):1689-702. PubMed ID: 19397308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
    Kwatra D; Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
    Int J Pharm; 2010 Aug; 395(1-2):114-21. PubMed ID: 20573570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
    Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
    Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application and limitation of inhibitors in drug-transporter interactions studies.
    Wang Q; Strab R; Kardos P; Ferguson C; Li J; Owen A; Hidalgo IJ
    Int J Pharm; 2008 May; 356(1-2):12-8. PubMed ID: 18272304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.